Patients in the Veritac-2 study were randomized to receive a standard estrogen blocker called fulvestrant, or Arvinas' ...

The Chart of the Day belongs to the aerospace & defense company Rocket Labs (RKLB). I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy ...

Rocket Lab stock is up 5.5% through 10:10 a.m. ET Monday morning in response to the news.

Rocket Lab's Electron launch vehicle has established itself as a market leader, achieving a remarkable 100% mission success rate in 2024 and consistently demonstrating high launch frequency and rapid ...

Rocket Lab (NASDAQ: RKLB) stock stumbled 8.2% through 11:30 a.m. ET Wednesday, giving back some of its mammoth 30% gain from Tuesday, a gain arising from investor enthusiasm over newly inaugurated ...

If the experimental estrogen degrader delays tumor growth longer than the standard of care, this stock will rocket higher. In a few years, vepdegestrant sales could soar past $1 billion annually ...

Saturday's launch was the fourth of five planned missions for Kineis. Rocket Lab stock is up 5.5% through 10:10 a.m. ET Monday morning in response to the news. Mission success for Rocket Lab's ...